Singapore approves AffaMed Therapeutics drug for Ocular Inflammation
Overview
New Drug Application(NDA) approved for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis China's AffaMed Therapeutics, has obtained New Drug Application (NDA) from Singapore Health Sciences Authority (HSA) for DEXTENZA® (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
DEXTENZA Uses
DEXTENZA is approved in the U.S. and listed in Macau for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis.
AffaMed’s Novel Product
• AffaMed is developing DEXTENZA, the first physician-administered sustained-release intracanalicular insert available to patients in ASEAN countries and Greater China.
• DEXTENZA delivers a preservative-free dose of dexamethasone for up to 30 days with a single administration, thereby offering patients significant benefit and convenience versus current treatments which require multiple administrations of eye-drops per day.
Words from AffaMed.
"As the first NDA filing by AffaMed, the acceptance of our DEXTENZA NDA in Singapore represents an important milestone in our company's journey to successfully advance much-needed therapeutic candidates through regulatory pathways across multiple regions in Asia,"" said Vijay Karwal, Chief Executive Officer of AffaMed.
Saferty & Efficacy Study
AffaMed has initiated a registrational trial in Mainland China to evaluate the safety and efficacy of DEXTENZA versus a placebo vehicle in the treatment of inflammation and pain following cataract surgery, and anticipates sharing topline data from this study in Q3 2024.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!